Somerset-based Catalent Inc. has launched a $200 million investment into its biologics business to expand its drug manufacturing capacity, it announced Monday.
The investment, phased over three years, will happen at the company’s biologics manufacturing sites in Madison, Wisconsin and Bloomington, Indiana.
The company said mammalian cell culture capacity will be increased in Madison with the build out of two new suites. Work is expected to be completed by mid-2021 and will more than double the company’s commercial biomanufacturing capacity, it said.
In addition, fill/finish capacity will be expanded at its 875,000-square-foot Bloomington site by 79,000 square feet.
“The expansions at both sites will support our customers’ development programs and commercial launches,” Barry Littlejohns, president, Catalent biologics and specialty drug delivery, said. “Catalent’s continued investments in innovative technologies and flexible capacity allow us to offer the most comprehensive solutions to bring important and innovative treatments to market faster.”